PT-2385 manufacturers
- PT-2385
-
- $61.00
-
2026-05-11
- CAS:1672665-49-4
- Purity: 99.54%
- Supply Ability: 10g
|
| | PT-2385 Basic information |
| Product Name: | PT-2385 | | Synonyms: | CS-2108;PT 2385;PT-2385;PT-2385;Benzonitrile, 3-[[(1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl]oxy]-5-fluoro-;(S)-3-(2,2-Difluoro-1-hydroxy-7-methanesulfonyl-indan-4-yloxy)-5-fluoro-benzonitrile;(S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile;Inhibitor,inhibit,Hypoxia-inducible factors,HIF/HIF Prolyl-Hydroxylase,HIF-PH,PT 2385,HIFs,PT-2385,PT2385;(methylsulfonyl) | | CAS: | 1672665-49-4 | | MF: | C17H12F3NO4S | | MW: | 383.34 | | EINECS: | | | Product Categories: | | | Mol File: | 1672665-49-4.mol |  |
| | PT-2385 Chemical Properties |
| Boiling point | 524.7±50.0 °C(Predicted) | | density | 1.57±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | DMSO:50.0(Max Conc. mg/mL);130.43(Max Conc. mM) | | pka | 11.28±0.40(Predicted) | | form | Solid | | color | White to off-white |
| | PT-2385 Usage And Synthesis |
| Uses | PT2385 is a HIF-2α antagonist with EC50 of 27 nM in the luciferase assay, with no apparent off-target effects. | | in vivo | PT-2385 (30 or 100 mg/kg; oral gavage; twice daily) result in a rapid, dose-dependent tumor regression[3].
PT-2385 (PT2385) inhibits expression of HIF-2α regulated genes in a dose dependent manner in vivo. Tumor is regressed with PT-2385 (3 and 10 mg/kg, p.o., b.i.d. dose) in 786-O xenograft. PT-2385 (1,3 and 10 mg/kg) also inhibits tumor-derived VEGFA protein levels. PT-2385 (10 mg/kg) treatment reduces proliferation (Ki67) and angiogenesis (CD-31)[1]. | Animal Model: | SCID/beige mice with the 786-O and A498 RCC cell lines[3] | | Dosage: | 30 or 100 mg/kg | | Administration: | Oral gavage; twice daily | | Result: | Resulted in a rapid, dose-dependent tumor regression.
|
|
| | PT-2385 Preparation Products And Raw materials |
|